Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.57 |
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410129 | 1.00 | ALK (0.57) | ALKJAK3JAK2PTK2EGFR | |
| SCHEMBL20412675 | 0.93 | ALK (0.56) | ALKJAK3JAK2PTK2EGFR | |
| SCHEMBL18410124 | 0.93 | ALK (0.60) | ALKJAK3JAK2PTK2EGFR | |
| SCHEMBL18410084 | 0.92 | ALK (0.47) | ALKJAK3JAK2JAK1TYK2 | |
| SCHEMBL18410126 | 0.92 | ALK (0.65) | ALKJAK3JAK2PTK2EGFR | |
| SCHEMBL18410133 | 0.91 | JAK3 (0.54) | ALKJAK3JAK2PTK2EGFR | |
| SCHEMBL20429850 | 0.91 | ALK (0.54) | ALKJAK3JAK2PTK2EGFR | |
| Nefextinib SCHEMBL29433596 | 0.86 | ALK (0.54) | ALKJAK3JAK2PTK2JAK1 | |
| Nefextinib SCHEMBL30274682 | 0.86 | ALK (0.54) | ALKJAK3JAK2PTK2JAK1 | |
| Nefextinib SCHEMBL18410078 | 0.86 | ALK (0.54) | ALKJAK3JAK2PTK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473300-B2 | Thienopyrimidine derivative and preparation method therefor | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20230144170-A1 | THIENOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473300-B2 | Thienopyrimidine derivative and preparation method therefor | DPYD, WEE1, TYMP | ALK 1154/4885JAK3 1963/4885JAK2 1497/4885 |
| US-20230144170-A1 | THIENOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR | DPYD, WEE1, TYMP | ALK 1154/4885JAK3 1963/4885JAK2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.